XSpray Pharma AB Total Liabilities

Latest as of June 2026: Skr173.68 Million SEK ≈ $18.69 Million USD

XSpray Pharma AB total liabilities. Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has total liabilities worth Skr173.68 Million SEK (≈ $18.69 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of XSpray Pharma AB to evaluate the company's liquid asset resilience ratio.

Total Liabilities of XSpray Pharma AB (2015–2025)

Total liabilities of XSpray Pharma AB from 2015 to 2025. This chart illustrates how XSpray Pharma AB's total liabilities have evolved over time, based on quarterly financial data.

XSpray Pharma AB Competitors by Total Liabilities

The table below lists competitors of XSpray Pharma AB ranked by their total liabilities.

Company	Country	Total Liabilities
Kyungdong Gas KO:012320	Korea	₩115.39 Billion
Hindustan Media Ventures Limited NSE:HMVL	India	Rs8.78 Billion
Oriental Food Industries Hold KLSE:7107	Malaysia	RM78.50 Million
AWC Berhad KLSE:7579	Malaysia	RM191.90 Million
SG Co. Ltd KQ:255220	Korea	₩124.11 Billion
ENERGY TRANSITION MINERAL F:G7PA	Germany	€6.17 Million
Croda International PLC LSE:CRDA	UK	GBX1.23 Billion
Gateway Real Estate AG XETRA:GTY	Germany	€1.18 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down XSpray Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see XSPRAY current and non-current assets.

Liquidity & Leverage Metrics

XSpray Pharma AB Total Liabilities Ratios Explained

XSpray Pharma AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.39	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.27	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.21	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how XSpray Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for XSpray Pharma AB (2015–2025)

The table below shows the annual total liabilities of XSpray Pharma AB from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr164.70 Million ≈ $17.72 Million	-4.94%
2024-12-31	Skr173.25 Million ≈ $18.64 Million	+141.12%
2023-12-31	Skr71.85 Million ≈ $7.73 Million	+144.30%
2022-12-31	Skr29.41 Million ≈ $3.17 Million	-5.59%
2021-12-31	Skr31.15 Million ≈ $3.35 Million	+37.13%
2020-12-31	Skr22.72 Million ≈ $2.44 Million	-15.73%
2019-12-31	Skr26.96 Million ≈ $2.90 Million	+150.32%
2018-12-31	Skr10.77 Million ≈ $1.16 Million	+87.17%
2017-12-31	Skr5.75 Million ≈ $619.17K	+6.78%
2016-12-31	Skr5.39 Million ≈ $579.83K	+100.45%
2015-12-31	Skr2.69 Million ≈ $289.27K	--

About XSpray Pharma AB

ST:XSPRAY Sweden Biotechnology

Market Cap

$61.44 Million

Skr570.90 Million SEK

Market Cap Rank

#20916 Global

#376 in Sweden

Share Price

Skr12.04

Change (1 day)

+2.91%

52-Week Range

Skr9.20 - Skr36.15

All Time High

Skr258.00